Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-06-15Clinical Trial Update: Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma [Phase 3]
Phase 3 trial update evaluating frailty-adjusted therapy for transplant non-eligible patients with newly diagnosed multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: Unrelated Umbilical Cord Blood (UBC)Transplantation [NA]
Clinical trial update for unrelated umbilical cord blood transplantation; the study is completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-06-07Clinical Trial Update: Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients [Phase 2]
Phase 2 clinical trial investigating propranolol to reduce stress-mediated gene expression pathways in hematopoietic stem cell transplant re…
-
CLINICAL_TRIALS trial_result · 2021-05-27Clinical Trial Update: Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma [Phase 2]
Phase II study update evaluating a combination of Biaxin, Revlimid, and dexamethasone for untreated multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2021-05-26Clinical Trial Update: Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants [Phase 4]
Phase 4 clinical trial evaluating zoledronic acid given every 4 or 12 weeks to prevent skeletal-related events in advanced multiple myeloma;…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-05-21Clinical Trial Update: Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma [Phase 2]
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for multiple myeloma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-05-19Clinical Trial Update: Safety and Efficacy Assessments of Osalmid in Multiple Myeloma [Phase 1, Phase 2]
Early-phase clinical trial update evaluating safety and efficacy of Osalmid in patients with Multiple Myeloma (Phase 1/2).
-
CLINICAL_TRIALS trial_result · 2021-05-18Clinical Trial Update: Selinexor in Combination With Thalidomide and Dexamethasone in RRMM [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating selinexor in combination with thalidomide and dexamethasone for relapsed/refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2021-05-14Clinical Trial Update: UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment [Phase 2]
Phase II prospective evaluation of bone remodeling during ixazomib treatment in patients with multiple myeloma completed with results posted…
-
CLINICAL_TRIALS trial_result · 2021-05-10Clinical Trial Update: Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma [NA]
Clinical trial update describing a study of bortezomib and filgrastim to promote stem cell mobilization in patients with various B-cell non-…
-
CLINICAL_TRIALS trial_result · 2021-04-30Clinical Trial Update: Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) [Phase 3]
A Phase 3 trial evaluating vorinostat (MK-0683) or placebo plus bortezomib in participants with multiple myeloma has completed with results …
-
CLINICAL_TRIALS trial_result · 2021-04-28Clinical Trial Update: An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients [Phase 2]
Phase 2 trial evaluating intensive quadruplet induction and consolidation with tandem autologous stem cell transplantation in newly diagnose…
-
CLINICAL_TRIALS trial_result · 2021-04-27Clinical Trial Update: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma [Phase 1]
Phase 1 trial of oprozomib with pomalidomide and dexamethasone in adults with primary refractory or relapsed and refractory multiple myeloma…
-
CLINICAL_TRIALS trial_result · 2021-04-26Clinical Trial Update: Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM) [Phase 1, Phase 2]
Phase 1/2 clinical trial exploring busulfan, melphalan, and escalating carfilzomib conditioning for autologous stem cell transplantation in …
-
CLINICAL_TRIALS trial_result · 2021-04-20Clinical Trial Update: Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating avelumab with hypofractionated radiotherapy in relapsed/refractory multiple myeloma; study terminated with results …
-
CLINICAL_TRIALS trial_result · 2021-04-14Clinical Trial Update: Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM [Phase 3]
Phase 3 trial comparing lenalidomide versus placebo maintenance after induction therapy in newly diagnosed multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2021-04-09Clinical Trial Update: Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) [Phase 1]
Phase I study of MK-0683 in combination with bortezomib in multiple myeloma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) [Phase 1]
Phase 1 study of pembrolizumab in combination with standard of care treatments for multiple myeloma was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-03-16Clinical Trial Update: Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma [Phase 2]
Phase 2 clinical trial comparing F-18 FDG and C-11 acetate PET in multiple myeloma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-03-10Clinical Trial Update: Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment [Phase 3]
Phase 3 trial comparing pom-dex vs pom-cyclo-dex in multiple myeloma patients during lenalidomide maintenance; study terminated with posted …
-
CLINICAL_TRIALS trial_result · 2021-03-03Clinical Trial Update: Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) [Phase 2]
The National Cancer Institute’s MATCH subprotocol R Phase 2 trial is evaluating trametinib as a targeted therapy for cancers with BRAF genet…
-
CLINICAL_TRIALS trial_result · 2021-03-03Clinical Trial Update: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial investigating oprozomib with dexamethasone in combination with lenalidomide or oral cyclophosphamide for newly diagnosed mul…
-
CLINICAL_TRIALS trial_result · 2021-03-01Clinical Trial Update: Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating melphalan and radiation therapy followed by lenalidomide in patients undergoing autologous stem cell transplant f…
-
CLINICAL_TRIALS trial_result · 2021-03-01Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155) [Phase 1]
Phase 1 study of pembrolizumab in combination with dinaciclib in hematologic malignancies was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-02-23Clinical Trial Update: An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells [Phase 2]
Phase 2 exploratory safety trial comparing G-CSF alone versus G-CSF plus plerixafor in multiple myeloma patients who may be poor mobilizers,…